HRP20020765A2 - Oxazolidinone tablet formulation - Google Patents

Oxazolidinone tablet formulation Download PDF

Info

Publication number
HRP20020765A2
HRP20020765A2 HR20020765A HRP20020765A HRP20020765A2 HR P20020765 A2 HRP20020765 A2 HR P20020765A2 HR 20020765 A HR20020765 A HR 20020765A HR P20020765 A HRP20020765 A HR P20020765A HR P20020765 A2 HRP20020765 A2 HR P20020765A2
Authority
HR
Croatia
Prior art keywords
linezolid
compressed tablet
hydroxypropylcellulose
microcrystalline cellulose
magnesium stearate
Prior art date
Application number
HR20020765A
Other languages
English (en)
Croatian (hr)
Inventor
Homer Lin
Ken Yamamoto
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22703542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020765(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HRP20020765A2 publication Critical patent/HRP20020765A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HR20020765A 2000-03-22 2001-03-15 Oxazolidinone tablet formulation HRP20020765A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19096900P 2000-03-22 2000-03-22

Publications (1)

Publication Number Publication Date
HRP20020765A2 true HRP20020765A2 (en) 2003-12-31

Family

ID=22703542

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020765A HRP20020765A2 (en) 2000-03-22 2001-03-15 Oxazolidinone tablet formulation

Country Status (33)

Country Link
EP (1) EP1265608B1 (pl)
JP (1) JP2003527424A (pl)
KR (2) KR20070094673A (pl)
CN (1) CN1208058C (pl)
AR (1) AR033357A1 (pl)
AT (1) ATE412413T1 (pl)
AU (2) AU2001243243B2 (pl)
BG (1) BG107117A (pl)
BR (1) BR0108846A (pl)
CA (1) CA2400118A1 (pl)
CZ (1) CZ20023133A3 (pl)
DE (1) DE60136341D1 (pl)
DK (1) DK1265608T3 (pl)
EA (1) EA006772B1 (pl)
EC (1) ECSP013979A (pl)
ES (1) ES2312422T3 (pl)
HK (1) HK1054325B (pl)
HR (1) HRP20020765A2 (pl)
HU (1) HUP0300378A3 (pl)
IL (1) IL151788A0 (pl)
MX (1) MXPA02009316A (pl)
MY (1) MY136370A (pl)
NO (1) NO20024505D0 (pl)
NZ (1) NZ521525A (pl)
PE (2) PE20011126A1 (pl)
PL (1) PL201686B1 (pl)
PT (1) PT1265608E (pl)
SK (1) SK12092002A3 (pl)
TW (1) TWI293028B (pl)
UA (1) UA77654C2 (pl)
WO (1) WO2001070225A2 (pl)
YU (1) YU69802A (pl)
ZA (1) ZA200207073B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DK1749517T3 (da) * 2005-07-20 2008-11-03 Teva Pharma Stabil farmaceutiske sammensætning af linezolid form IV
WO2010026597A1 (en) * 2008-09-02 2010-03-11 Hetero Research Foundation Oral dosage forms of linezolid and processes for their preparation
AU2011332031B2 (en) 2010-11-24 2017-01-12 Melinta Subsidiary Corp. Pharmaceutical compositions
WO2013088389A1 (en) * 2011-12-14 2013-06-20 Alembic Pharmaceuticals Limited Linezolid premix
CN103505459B (zh) * 2012-06-20 2016-02-24 北京万生药业有限责任公司 利奈唑胺药物组合物
CN104622831B (zh) * 2013-11-06 2018-06-22 江苏豪森药业集团有限公司 一种口服片剂及其制备方法
US11324734B2 (en) * 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia
CN106727396A (zh) * 2016-11-22 2017-05-31 湖北广济药业股份有限公司 一种ⅱ晶型利奈唑胺片及其制备方法
CN109481412A (zh) * 2018-08-17 2019-03-19 扬子江药业集团北京海燕药业有限公司 一种ii晶型利奈唑胺片及其制备工艺

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993767A (en) * 1975-11-18 1976-11-23 A. H. Robins Company, Incorporated Compositions to suppress gastric bleeding in indomethacin and phenylbutazone therapy
AUPP437698A0 (en) * 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
ES2203473T3 (es) * 1999-05-27 2004-04-16 PHARMACIA & UPJOHN COMPANY Oxazolidinonas biciclicas como agentes antibacterianos.

Also Published As

Publication number Publication date
DK1265608T3 (da) 2008-12-08
NO20024505L (no) 2002-09-20
CN1418097A (zh) 2003-05-14
NZ521525A (en) 2004-02-27
EA200201006A1 (ru) 2003-02-27
ATE412413T1 (de) 2008-11-15
KR20020083185A (ko) 2002-11-01
CA2400118A1 (en) 2001-09-27
MY136370A (en) 2008-09-30
PT1265608E (pt) 2008-12-15
NO20024505D0 (no) 2002-09-20
HUP0300378A2 (hu) 2003-06-28
WO2001070225A2 (en) 2001-09-27
PE20020499Z (es) 2002-07-12
ES2312422T3 (es) 2009-03-01
IL151788A0 (en) 2003-04-10
HUP0300378A3 (en) 2004-11-29
AU2001243243B2 (en) 2004-10-14
PL201686B1 (pl) 2009-04-30
PE20011126A1 (es) 2001-10-31
PL366067A1 (pl) 2005-01-24
MXPA02009316A (es) 2004-04-05
DE60136341D1 (de) 2008-12-11
EP1265608B1 (en) 2008-10-29
CZ20023133A3 (cs) 2003-01-15
UA77654C2 (en) 2007-01-15
KR100786410B1 (ko) 2007-12-17
SK12092002A3 (sk) 2002-12-03
HK1054325B (zh) 2006-01-13
ECSP013979A (es) 2002-01-25
AU4324301A (en) 2001-10-03
EP1265608A2 (en) 2002-12-18
AR033357A1 (es) 2003-12-17
KR20070094673A (ko) 2007-09-20
ZA200207073B (en) 2003-12-03
TWI293028B (en) 2008-02-01
JP2003527424A (ja) 2003-09-16
BG107117A (bg) 2003-05-30
BR0108846A (pt) 2003-05-06
EA006772B1 (ru) 2006-04-28
HK1054325A1 (zh) 2003-11-28
WO2001070225A3 (en) 2001-12-13
YU69802A (sh) 2005-11-28
CN1208058C (zh) 2005-06-29

Similar Documents

Publication Publication Date Title
AU2010318049A1 (en) Propane-I-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-B]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
CA2547113A1 (en) Method for the production of a solid, orally applicable pharmaceutical composition
US6514529B2 (en) Oxazolidinone tablet formulation
HRP20020765A2 (en) Oxazolidinone tablet formulation
WO2009042809A1 (en) Stable imatinib compositions
CN102802615A (zh) 新瑞替加滨组合物
NZ503413A (en) Particle compositions of lipid lowering agents
AU2001243243A1 (en) Oxazolidinone tablet formulation
WO2007102082A1 (en) High oxazolidinone content solid dosage forms
JP2009501794A (ja) リネゾリドの形態ｉｖを含む安定な医薬組成物
KR19990022537A (ko) 알칼리화 포타슘염 조절 방출제제
WO2012029074A2 (en) Pharmaceutical compositions of linezolid
WO2010125572A1 (en) Compressed tablets and capsules containing efavirenz
CN101560209B (zh) 含有嘧啶的噁唑烷酮类化合物及其制备方法
CN101209974A (zh) 异羟肟酸类衍生物及其用途
CA2499149A1 (en) Mannitol formulation for integrin receptor antagonist
UA81760C2 (uk) Фармацевтична композиція для перорального застосування етилового ефіру 3-[(2-{[4-(гексилоксикарбоніламіноімінометил)феніламіно]метил}-1-метил-1н-бензімідазол-5-карбоніл)піридин-2-іламіно]пропіонової кислоти та спосіб її одержання
US20010046992A1 (en) Treatment of urinary tract infections with antibacterial oxazolidinones
WO2008101139A1 (en) Sustained-release tablet formulations of piperazine-piperidine antagonists and agonists of the 5-ht1a receptor having enhanced intestinal dissolution
WO2025078941A1 (en) Pharmaceutical composition of pirtobrutinib
JP2021116239A (ja) 溶出制御されたダサチニブ無水物含有医薬組成物
CN103509004A (zh) 达比加群酯咖啡酸盐及其制备方法和应用
CN103570680A (zh) 达比加群酯果糖酸盐及其制备方法和应用

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODBC Application rejected